Eugia Pharma Receives USFDA Approval for Triamcinolone Acetonide Injectable Suspension 200 mg/5 mL & 400 mg/‌10 mL MDV

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Triamcinolone Acetonide Injectable Suspension 200 mg/5 mL & 400 mg/‌10 mL MDV.

Indications for this product include:

For Intramuscular and Intra-Articular use only.

• Intramuscular – Where oral therapy is not feasible: allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases (palliative treatment), nervous system, ophthalmic diseases, renal diseases, respiratory diseases, rheumatic disorders.
• Intra-Articular – adjunctive therapy for short-term administration in: acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

Refer to package insert for full prescribing information.